FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody specifically binding to CXCR4 and its antigen-binding fragment, a nucleic acid encoding the above antibody or fragment thereof, a vector, a host cell containing the aforementioned nucleic acid, and a method for production of this antibody or a fragment thereof. Also a murine hybridoma deposited in the National Collection of Microorganism Cultures on June 25, 2008 under the number I-4018 is disclosed. The invention also relates to diagnostic methods using the above antibody or a fragment thereof, as well as a kit for their implementation.
EFFECT: invention allows efficient diagnosis of diseases characterized by CXCR4 expression.
30 cl, 8 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR TUMOURS VOLUME REDUCTION | 2010 |
|
RU2627163C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706959C2 |
| ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODY IN HETERODIMERIC FORM, SIMILAR IN STRUCTURE TO NATURAL ANTIBODY, AND PRODUCTION THEREOF | 2022 |
|
RU2825838C1 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
